Arthur KlausnerPresident and CEO at Goldilocks Therapeutics, Inc.
Arthur Klausner is President and CEO of Goldilocks Therapeutics, Inc., a start-up company formed to advance proprietary nanoparticle technology developed at Memorial Sloan Kettering Cancer Center for the prevention/treatment of underserved kidney conditions. He had previously served as CEO and a Boardmember of Gem Pharmaceuticals (non-cardiotoxic doxorubicin analog vs. cancer that was acquired by Monopar Therapeutics in 2017), and CEO and a Boardmember of Jade Therapeutics (ophthalmic applications of a cross-linked hyaluronic acid polymer that was acquired by EyeGate Pharmaceuticals in 2016). Prior to his operating roles, Klausner spent a total of 18 years as a life sciences venture capitalist at Domain Associates and Pappas Ventures. During that time, he was involved in the investment in and subsequent nurturing of a variety of biotechnology, specialty pharmaceutical, and medical device companies. Klausner has been a board member at Santarus (IPO in 2004), X-Ceptor (acquired by Exelixis in 2004), Orexigen (IPO in 2007), and Syndax Pharmaceuticals (IPO in 2016), and a board observer at Peninsula Pharmaceuticals (acquired by Johnson & Johnson in 2005) and Cerexa (acquired by Forest Laboratories in 2007), among others. He currently serves on the Board of Directors of Goldilocks Therapeutics and Monopar Therapeutics, as well as on Advisory Boards for the New York University Innovation Venture Fund and 1st Pitch Life Science.